Literature DB >> 22101116

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.

Robert J Klein1, Christer Hallden, Amit Gupta, Caroline J Savage, Anders Dahlin, Anders Bjartell, Jonas Manjer, Peter T Scardino, David Ulmert, Peter Wallström, Andrew J Vickers, Hans Lilja.   

Abstract

BACKGROUND: Although case-control studies have identified numerous single nucleotide polymorphisms (SNPs) associated with prostate cancer, the clinical role of these SNPs remains unclear.
OBJECTIVE: Evaluate previously identified SNPs for association with prostate cancer and accuracy in predicting prostate cancer in a large prospective population-based cohort of unscreened men. DESIGN, SETTING, AND PARTICIPANTS: This study used a nested case-control design based on the Malmö Diet and Cancer cohort with 943 men diagnosed with prostate cancer and 2829 matched controls. Blood samples were collected between 1991 and 1996, and follow-up lasted through 2005. MEASUREMENTS: We genotyped 50 SNPs, analyzed prostate-specific antigen (PSA) in blood from baseline, and tested for association with prostate cancer using the Cochran-Mantel-Haenszel test. We further developed a predictive model using SNPs nominally significant in univariate analysis and determined its accuracy to predict prostate cancer. RESULTS AND LIMITATIONS: Eighteen SNPs at 10 independent loci were associated with prostate cancer. Four independent SNPs at four independent loci remained significant after multiple test correction (p<0.001). Seven SNPs at five independent loci were associated with advanced prostate cancer defined as clinical stage≥T3 or evidence of metastasis at diagnosis. Four independent SNPs were associated with advanced or aggressive cancer defined as stage≥T3, metastasis, Gleason score≥8, or World Health Organization grade 3 at diagnosis. Prostate cancer risk prediction with SNPs alone was less accurate than with PSA at baseline (area under the curve of 0.57 vs 0.79), with no benefit from combining SNPs with PSA. This study is limited by our reliance on clinical diagnosis of prostate cancer; there are likely undiagnosed cases among our control group.
CONCLUSIONS: Only a few previously reported SNPs were associated with prostate cancer risk in the large prospective Diet and Cancer cohort in Malmö, Sweden. SNPs were less useful in predicting prostate cancer risk than PSA at baseline.
Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22101116      PMCID: PMC3269546          DOI: 10.1016/j.eururo.2011.10.047

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  30 in total

1.  Cumulative association of five genetic variants with prostate cancer.

Authors:  S Lilly Zheng; Jielin Sun; Fredrik Wiklund; Shelly Smith; Pär Stattin; Ge Li; Hans-Olov Adami; Fang-Chi Hsu; Yi Zhu; Katarina Bälter; A Karim Kader; Aubrey R Turner; Wennuan Liu; Eugene R Bleecker; Deborah A Meyers; David Duggan; John D Carpten; Bao-Li Chang; William B Isaacs; Jianfeng Xu; Henrik Grönberg
Journal:  N Engl J Med       Date:  2008-01-16       Impact factor: 91.245

2.  Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk.

Authors:  Claudia A Salinas; Erika Kwon; Christopher S Carlson; Joseph S Koopmeiners; Ziding Feng; Danielle M Karyadi; Elaine A Ostrander; Janet L Stanford
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-05       Impact factor: 4.254

3.  The Malmö Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants.

Authors:  J Manjer; S Carlsson; S Elmståhl; B Gullberg; L Janzon; M Lindström; I Mattisson; G Berglund
Journal:  Eur J Cancer Prev       Date:  2001-12       Impact factor: 2.497

4.  Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.

Authors:  Gianluca Severi; Vanessa M Hayes; Petra Neufing; Emma J D Padilla; Wayne D Tilley; Sarah A Eggleton; Howard A Morris; Dallas R English; Melissa C Southey; John L Hopper; Robert L Sutherland; Peter Boyle; Graham G Giles
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-06       Impact factor: 4.254

5.  Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study.

Authors:  Mattias Johansson; Benny Holmström; Sally R Hinchliffe; Anders Bergh; Ulf-Håkan Stenman; Göran Hallmans; Fredrik Wiklund; Pär Stattin
Journal:  Int J Cancer       Date:  2011-04-01       Impact factor: 7.396

6.  Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans.

Authors:  S Lilly Zheng; Jielin Sun; Yu Cheng; Ge Li; Fang-Chi Hsu; Yi Zhu; Bao-Li Chang; Wennuan Liu; Jin Woo Kim; Aubrey R Turner; Marta Gielzak; Guifang Yan; Sarah D Isaacs; Kathleen E Wiley; Jurga Sauvageot; Huann-Sheng Chen; Robin Gurganus; Leslie A Mangold; Bruce J Trock; Henrik Gronberg; David Duggan; John D Carpten; Alan W Partin; Patrick C Walsh; Jianfeng Xu; William B Isaacs
Journal:  J Natl Cancer Inst       Date:  2007-10-09       Impact factor: 13.506

Review 7.  Familial prostate cancer in Sweden. A nationwide register cohort study.

Authors:  H Grönberg; L Damber; J E Damber
Journal:  Cancer       Date:  1996-01-01       Impact factor: 6.860

8.  Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12.

Authors:  Jielin Sun; Siqun Lilly Zheng; Fredrik Wiklund; Sarah D Isaacs; Lina D Purcell; Zhengrong Gao; Fang-Chi Hsu; Seong-Tae Kim; Wennuan Liu; Yi Zhu; Pär Stattin; Hans-Olov Adami; Kathleen E Wiley; Latchezar Dimitrov; Jishan Sun; Tao Li; Aubrey R Turner; Tamara S Adams; Jan Adolfsson; Jan-Erik Johansson; James Lowey; Bruce J Trock; Alan W Partin; Patrick C Walsh; Jeffrey M Trent; David Duggan; John Carpten; Bao-Li Chang; Henrik Grönberg; William B Isaacs; Jianfeng Xu
Journal:  Nat Genet       Date:  2008-08-31       Impact factor: 38.330

9.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

10.  Power analysis for genome-wide association studies.

Authors:  Robert J Klein
Journal:  BMC Genet       Date:  2007-08-28       Impact factor: 2.797

View more
  28 in total

1.  Prostate Cancer Risk-Associated Single-Nucleotide Polymorphism Affects Prostate-Specific Antigen Glycosylation and Its Function.

Authors:  Srilakshmi Srinivasan; Carson Stephens; Emily Wilson; Janaththani Panchadsaram; Kerry DeVoss; Hannu Koistinen; Ulf-Håkan Stenman; Mark N Brook; Ashley M Buckle; Robert J Klein; Hans Lilja; Judith Clements; Jyotsna Batra
Journal:  Clin Chem       Date:  2018-12-11       Impact factor: 8.327

Review 2.  Prostate cancer in young men: an important clinical entity.

Authors:  Claudia A Salinas; Alex Tsodikov; Miriam Ishak-Howard; Kathleen A Cooney
Journal:  Nat Rev Urol       Date:  2014-05-13       Impact factor: 14.432

3.  Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.

Authors:  Weiqiang Li; Mridu Middha; Mesude Bicak; Daniel D Sjoberg; Emily Vertosick; Anders Dahlin; Christel Häggström; Göran Hallmans; Ann-Charlotte Rönn; Pär Stattin; Olle Melander; David Ulmert; Hans Lilja; Robert J Klein
Journal:  Eur Urol       Date:  2018-07-07       Impact factor: 20.096

4.  Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.

Authors:  A Karim Kader; Michael A Liss; Greg Trottier; Seong-Tae Kim; Jielin Sun; S Lilly Zheng; Karen Chadwick; Gina Lockwood; Jianfeng Xu; Neil E Fleshner
Journal:  Urology       Date:  2015-01       Impact factor: 2.649

Review 5.  Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.

Authors:  Stacy Loeb; Hans Lilja; Andrew Vickers
Journal:  Curr Opin Urol       Date:  2016-09       Impact factor: 2.309

6.  Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes.

Authors:  Shancheng Ren; Jianfeng Xu; Tie Zhou; Haowen Jiang; Haitao Chen; Fang Liu; Rong Na; Limin Zhang; Yishuo Wu; Jielin Sun; Bo Yang; Xu Gao; S Lilly Zheng; Chuanliang Xu; Qiang Ding; Yinghao Sun
Journal:  Prostate       Date:  2013-08-26       Impact factor: 4.104

7.  Prostate cancer risk-associated genetic markers and their potential clinical utility.

Authors:  Jianfeng Xu; Jielin Sun; S Lilly Zheng
Journal:  Asian J Androl       Date:  2013-04-08       Impact factor: 3.285

8.  Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men.

Authors:  Charlotta Sävblom; Christer Halldén; Angel M Cronin; Torbjörn Säll; Caroline Savage; Emily A Vertosick; Robert J Klein; Aleksander Giwercman; Hans Lilja
Journal:  Clin Chem       Date:  2013-11-22       Impact factor: 8.327

9.  Comprehensive Analysis of Multiple Cohort Datasets Deciphers the Utility of Germline Single-Nucleotide Polymorphisms in Prostate Cancer Diagnosis.

Authors:  Wensheng Zhang; Yan Dong; Oliver Sartor; Kun Zhang
Journal:  Cancer Prev Res (Phila)       Date:  2021-04-17

10.  Genome-wide association study identifies novel single nucleotide polymorphisms having age-specific effect on prostate-specific antigen levels.

Authors:  Weiqiang Li; Mesude Bicak; Daniel D Sjoberg; Emily Vertosick; Anders Dahlin; Olle Melander; David Ulmert; Hans Lilja; Robert J Klein
Journal:  Prostate       Date:  2020-09-11       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.